Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
13,878 total articles
Recent headlines about high-profile departures at Alphabet have rattled investors, but the company’s core business, cash generation, and strategic position in AI and advertising make this a tactical buying opportunity. This trade idea lays out an actionable mid-term long with explicit entry, stop, and target levels and explains the key catalysts an…
Talen Energy (TLN) is a differentiated utility-like play with merchant exposure - its June acquisition of three efficient PJM plants, plus refinancing that trims annual interest by over $40M, creates near-term cash flow upside and a clearer path to de-levering. Valuation is not cheap on headline multiples, but free cash flow and the accretive natur…
Parex Resources is a concentrated, Colombia-focused oil producer whose headline volatility creates a trade-worthy risk/reward profile. This idea lays out a clear entry, profit target and stop, and explains why operational catalysts and a relatively low trading multiple make a long position attractive over the next 180 trading days.
Lakeland (LAKE) is cheap by headline multiples — $109M market cap, EV/Sales ~0.62, P/B ~0.84 — but the stock is a binary bet tied to operational fixes and certification milestones for recent acquisitions. If management can show sustained production and certification progress, the shares can re-rate quickly. If not, legal overhangs and negative cash…
Mueller Water Products (MWA) trades at $24.92 with a market cap of $3.90B and an EV/EBITDA of 11.5. Strong margins, high return on equity (19.37%), and $141.2M of free cash flow underpin a mid-term long trade. I recommend entering at $24.92, a stop at $22.70, and a primary target of $29.50 over ~45 trading days, with a secondary target of $32.00 if…
Adobe's shares have been punished in H1 2026, but the company's cash flow, low effective multiple, and exposure to accelerating Document AI and generative-video demand create an asymmetric risk-reward. This trade idea lays out a precise entry at $224.00, a stop at $200.00, and a target of $280.00 for a mid-term swing (11-45 trading days) with conti…
Salesforce is trading well below its prior highs despite healthy free cash flow, double-digit ROE and a reasonable EV multiple. This trade idea argues for a tactical long: the business fundamentals and AI/workflow tailwinds justify upside to $210 over a 180-trading-day horizon while risk is managed with a tight stop at $150.
Disney ($95.70) trades at an attractive multiple relative to its cash flow and historical optionality. Ongoing market chatter about Lionsgate and a steady slate of park and theatrical catalysts give bulls an asymmetric setup. Balance the upside of a re-rating and potential M&A benefit against execution risk at streaming and cyclical exposure in par…
SK hynix (SSNLF) is my preferred memory play over Micron (MU). The company combines aggressive technology roadmaps, improving gross margins from better product mix, and a valuation that still lags Micron despite similar cycle exposure. For disciplined traders, a long position in the ADR provides an asymmetric payoff as the industry enters an invent…
Flagstar looks vulnerable to ongoing deposit and commercial real-estate stress, but capital resilience and the possibility of an outsized recovery in spreads cap the payoff. This trade idea establishes a defined-risk short with a mid-term horizon, clear stop, and pragmatic targets keyed to continued earnings pressure and funding costs.
Lumentum (LITE) sits squarely in the path of hyperscaler capex for AI infrastructure. Strong customer commitments, a meaningful market cap with stretched but defendable fundamentals, and improving technicals make a mid-term long trade attractive. Plan: enter near current levels, limit risk with a tight stop, and target a move above the $900s as man…
NovoCure (NVCR) plunged after a trial-related setback but fundamentals, recent device approvals, and a pending FDA decision on additional TTFields indications in Q4 2026 create a favorable asymmetric risk/reward. Market cap sits near $2.0B, technicals show consolidation, and institutional short interest is elevated — ideal conditions for a discipli…
We reiterate our Buy on Uranium Royalty Company (UROY). Royalty exposure to a tightening uranium market, a capital-light business model and multiple near-term catalysts support upside. We lay out an actionable entry at $1.50, a $3.00 target and a $0.90 stop for a long-term (180 trading days) trade while highlighting the key risks that could derail …
TeraWulf (WULF) has quietly converted a portion of its bitcoin-mining footprint into utility-grade AI hosting capacity and just locked a 20-year, $19B lease with Anthropic for 401 MW. That deal materially improves revenue visibility and margin mix versus peers still concentrated in variable crypto rewards. The stock trades at ~$22.23 today with a m…
RxSight has retraced to the low end of its 52-week range after a year of headline risk and sales variability. With 2025 revenue coming in at $134.5M, accelerating procedure counts, a clean balance sheet (no debt) and attractive valuation versus revenue, a disciplined long trade looking for mean reversion and continued adoption makes sense. This is …
Byrna Technologies can build a compelling less-lethal product, but recent results show the harder job is turning product into repeat retail sales. With Q2 revenue down 43% YoY, a $10.4M impairment and production cuts, the risk-reward today favors a tactical short into weakness. Entry $3.95, stop $5.50, target $2.25 for a mid-term trade around 45 tr…
Stepan Co. looks inexpensive on headline multiples, but weakening earnings, thin recent trading, and rising short interest argue the market still has work to do on the downside. This is a tactical short trade sized for a mid-term horizon with a tight stop and a realistic target around prior support.
Micron is flush with AI-driven demand: record data-center margins, a revenue surge, and strategic auto supply deals. The stock is trading below recent short-term moving averages but fundamentals (free cash flow $26.2B, ROE 50%) argue for a tactical long. This trade sets a clear entry, stop and target for a mid-term swing (45 trading days) while ack…
MDA Space offers a way to play accelerating government and commercial spending on satellites, robotics and space systems. A $620M acquisition of Blue Canyon (06/26/2026) plus a C$688M Canadian contract give MDA direct access to U.S. defense programs and a $3.5B addressable pipeline. The stock is trading below key moving averages after a pullback; w…
Apollo Global Management (APO) trades nearer its 2026 lows but still sits on a $70B market cap with fee-bearing businesses, active deal flow and growing private-credit presence. Short-term headlines around private credit volatility have compressed sentiment and multiples; we view this as an opportunity for a mid-term swing trade that captures multi…
Corcept (CORT) cratered after a Complete Response Letter for relacorilant, but the company is cash-generative, debt-free and has rebuilt market value into 2026 highs. This trade idea buys the pullback/retest of recent strength with a defined stop and a 180-day time frame, accepting headline risk in exchange for 20%+ upside if catalysts materialize.
Viking Therapeutics (VKTX) remains compelling on fundamentals and momentum: a $4.5B market cap, attractive technicals and a late-stage obesity candidate that keeps the stock in play. That said, price action is carving a possible double-top near the 52-week high and short interest is meaningful — so risk management is essential. This is a swing trad…
POET Technologies dropped sharply after a high-profile order cancellation and a flurry of securities-law filings. With a market cap near $1.44B, a large installed technology moat in optical interposers, and technical indicators suggesting oversold conditions, the risk/reward favors a disciplined mid-term long. Trade plan, catalysts and clear stop m…
Clorox (CLX) trades near $96 with a 5.3% yield, a mid-teens P/E, and free cash flow of roughly $380M. Operational noise and a recent portfolio shuffle have pressured the stock; that creates a high-yield entry for investors willing to back brand strength and margin recovery over the next 180 trading days. This note lays out an actionable long trade …
Medtronic is a cash-generating medical-device franchise trading at a modest multiple, supported by AI-enabled surgical growth, a broad product portfolio, and a defensible dividend. This trade idea outlines a long entry at ~$83 with a $100 target over 180 trading days and a $75 stop — a risk-managed way to own a high-quality medtech name while key c…
